SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-022609
Filing Date
2023-05-17
Accepted
2023-05-17 08:07:30
Documents
15
Period of Report
2023-05-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-20230515.htm   iXBRL 8-K 94042
2 EX-10.1 achv-ex10_1.htm EX-10.1 1059796
3 EX-10.2 achv-ex10_2.htm EX-10.2 272537
  Complete submission text file 0000950170-23-022609.txt   1757746

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT achv-20230515_pre.xml EX-101.PRE 14084
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT achv-20230515_def.xml EX-101.DEF 13919
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT achv-20230515.xsd EX-101.SCH 2939
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT achv-20230515_lab.xml EX-101.LAB 21357
9 EXTRACTED XBRL INSTANCE DOCUMENT achv-20230515_htm.xml XML 6342
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 23929672
SIC: 2835 In Vitro & In Vivo Diagnostic Substances